Urologic Oncology Branch, Center for Cancer Research, NCI, Bethesda, Maryland.
Cancer Discov. 2017 Nov;7(11):1221-1223. doi: 10.1158/2159-8290.CD-17-0971.
Clear cell renal cell carcinoma (ccRCC) is characterized by loss of the von Hippel-Lindau tumor suppressor gene (), and the functional tumorigenic consequences of this loss have been used to develop therapies for advanced ccRCC, such as targeting activation of the HIF pathway. Yao and colleagues elucidate how VHL loss contributes to chromatin alteration at both gene promoters and enhancers/superenhancers, in both an HIF-dependent as well as independent manner, and how this may provide additional targets for therapeutic intervention in advanced ccRCC. .
透明细胞肾细胞癌（ccRCC）的特征是von Hippel-Lindau 肿瘤抑制基因 () 的缺失，而这种缺失的功能性肿瘤发生后果已被用于开发治疗晚期 ccRCC 的方法，例如靶向 HIF 通路的激活。Yao 及其同事阐明了 VHL 缺失如何以 HIF 依赖和非依赖的方式导致基因启动子和增强子/超级增强子处染色质改变，以及这如何为晚期 ccRCC 的治疗干预提供额外的靶点。
